BiotechTube

OCS-01 + Vehicle

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Inflammation Eye Pain

Conditions

Inflammation Eye Pain, Postoperative Cataract

Trial Timeline

Jun 24, 2022 → Jul 3, 2023

NCT ID
NCT05147233

About OCS-01 + Vehicle

OCS-01 + Vehicle is a phase 3 stage product being developed by Oculis Holding AG for Inflammation Eye Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05147233. Target conditions include Inflammation Eye Pain, Postoperative Cataract.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05147233Phase 3Completed

Competing Products

20 competing products in Inflammation Eye Pain

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterolMerckPhase 1
33
MAS825 + PlaceboNovartisPhase 2
52
Secukinumab s.c. injectionNovartisApproved
85
etanerceptAmgenPhase 3
76
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0114-0006 + placeboNovo NordiskPhase 2
51
NNC0114-0006 + placeboNovo NordiskPhase 1
32
NNC0109-0012 + placeboNovo NordiskPhase 2
51
NNC 0151-0000-0000 + NNC 0151-0000-0000 + placeboNovo NordiskPhase 1
32
catridecacog + placeboNovo NordiskPhase 2
51
NNC109-0012 + placeboNovo NordiskPhase 2
51
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0215-0384 + placeboNovo NordiskPhase 1
32
NNC 0151-0000-0000 + placeboNovo NordiskPhase 2
51

Other Products from Oculis Holding AG

Dexamethasone Ophthalmic SuspensionPhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 2/3
60
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + PlaceboPhase 2
47
OCS-01Phase 2
47